Vimarsana
Biggest News Aggregation in the World

Alpine Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alpine Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alpine Study Today - Breaking & Trending Today

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL) - Vimarsana News

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Published: December 20, 2023

Jennifer R. Brown, MD, PhD, presents data from the extended follow-up of the ALPINE study investigating zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Source: onclive.com
Related Topics:
San DiegoUnited StatesJenniferr BrownExtended Follow UpZanubrutinib Versus IbrutinibRefractory Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaPartnership WithAlpine StudyChronic Lymphocytic LeukemiaBtk InhibitorCll TreatmentAlpine TrialAlpine Study DataAlpine Study ResultsAlpine Extended Follow Up
CLL: Supportive Care and Managing Adverse Effects With BTK Inhibitors - Vimarsana News

CLL: Supportive Care and Managing Adverse Effects With BTK Inhibitors

Published: April 24, 2023

Insights on supportive care and approaches to managing adverse effects of BTK inhibitors in the treatment of chronic lymphocytic leukemia.

Source: curetoday.com
Related Topics:
Hoshiyuki IidaGloria LeslieChronic Lymphocytic LeukemiaAdverse EffectsAtrial FibrillationSupportive CareAlpine StudyBtk InhibitorsCovid 19
Head-to-Head Studies on BTK Inhibitors in CLL - Vimarsana News

Head-to-Head Studies on BTK Inhibitors in CLL

Published: April 17, 2023

CLL expert Lori A. Leslie, MD, gives a comprehensive overview of the ALPINE and ELEVATE-RR head-to-head studies of BTK inhibitors in CLL.

Source: curetoday.com
Related Topics:
Gloria LeslieChronic Lymphocytic LeukemiaCovalent Btk InhibitorsElevate RrDel 11q Del 17p Progression Free SurvivalToxicity ProfileAlpine StudyOverall ResponseAsh 2022 Annual Meeting